Walgreens — Opioid Prescription Fraud
Walgreens Pays $350 Million for Illegally Filling Opioid Prescriptions
Source: U.S. Department of Justice
TL;DR: Walgreens Pays $350 Million for Illegally Filling Opioid Prescriptions This case resulted in a $350 Million resolution and demonstrates the impact of whistleblower protections in recovering funds from fraud.
Summary
Walgreens and its subsidiaries agreed to pay $350 million, plus possible future payments contingent on revenue, to resolve False Claims Act and Controlled Substances Act allegations that they illegally filled invalid prescriptions for opioids and other controlled substances and sought payment from federal healthcare programs. DOJ alleged Walgreens pharmacies filled prescriptions despite clear red flags indicating the prescriptions lacked legitimate medical purpose. As part of the resolution, Walgreens entered into a Memorandum of Agreement with the DEA and a five-year Corporate Integrity Agreement with HHS-OIG.
Our Take
Retail pharmacy opioid cases typically involve system-wide failures in "corresponding responsibility"—the legal duty to verify prescriptions are legitimate before dispensing. Insiders often have access to the operational reality: pharmacist complaints about quotas, "do not fill" lists that were ignored, corporate pressure to minimize refusals, and red flag override patterns. The strongest evidence shows what leadership knew about suspicious prescribers and what they chose not to do about it.
Read the full article from the original source:
View Original ArticleOpens in a new tab. Content from U.S. Department of Justice.
Notice
The summaries above are based on publicly available information released by the U.S. Department of Justice and are provided for informational purposes only. They do not constitute legal advice, investigative findings, or allegations by Disclosure Strategy. Our commentary reflects general, experience-based observations about how False Claims Act matters commonly arise and is not a statement about any party's liability.